OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Ruan on the Evolving Armamentarium in MCL

November 16th 2020

Jia Ruan, MD, PhD, discusses the evolving armamentarium in mantle cell lymphoma.

Dr. Randall on the Evolution of Orthopedic Surgery in Sarcoma

November 16th 2020

R. Lor Randall, MD, FACS, discusses the evolution of orthopedic surgery in sarcoma.

Dr. Costello on Tailoring Induction Therapy for Standard- and High-Risk Multiple Myeloma

November 16th 2020

Caitlin Costello, MD, discusses tailoring induction therapy for patients with standard-risk and high-risk multiple myeloma.

Dr. Eng on the Role of Adjuvant Chemotherapy in CRC

November 16th 2020

Cathy Eng, MD, FACP, FASCO, discusses the role of adjuvant chemotherapy in colorectal cancer.

Dr. Jagadeesh on Unmet Needs in Aggressive and Rare Lymphoma Subtypes

November 14th 2020

Deepa Jagadeesh, MD, discusses unmet needs in aggressive and rare lymphoma subtypes.

Dr. Patel on Limitations With Chemotherapy in Pancreatic Cancer

November 14th 2020

Reema A. Patel, MD, discusses limitations with chemotherapy in pancreatic cancer.

Dr. Haas on the Role of PSMA in Prostate Cancer

November 14th 2020

Naomi B. Haas, MD, discusses the role of prostate-specific membrane antigen in prostate cancer.

Dr. Lee on the Rationale for Evaluating Telaglenastat in RCC

November 13th 2020

Chung-Han Lee, MD, PhD, discusses the rationale for evaluating telaglenastat in renal cell carcinoma.

Dr. Zalcberg on the Approval of Avapritinib in GIST

November 12th 2020

John Zalcberg, PhD, OAM, discusses the approval of avapritinib in gastrointestinal stromal tumor.

Dr. Baskin on Mitigating Patient Concerns During the COVID-19 Pandemic in Prostate Cancer

November 12th 2020

Monica L. Baskin, PhD, discusses mitigating patient concerns during the coronavirus disease 2019 pandemic in prostate cancer.

Dr. Vesole on the Mechanism of Action of Belantamab Mafodotin in Multiple Myeloma

November 12th 2020

David H. Vesole, MD, PhD, discusses the mechanism of action of belantamab mafodotin-blmf in multiple myeloma.

Dr. Saba Discusses Ongoing Trials in Head and Neck Cancer

November 12th 2020

Nabil F. Saba, MD, FACP, discusses ongoing clinical trials in head and neck cancer.

Dr. Bagegni on the Safety Profile of T-DM1 in Early-Stage HER2+ Breast Cancer

November 12th 2020

Nusayba Bagegni, MD, discusses the safety profile of ado-trastuzumab emtansine in early-stage HER2-positive breast cancer.

Dr. Brody on the Challenges of Antigen Escape in MCL

November 12th 2020

Joshua Brody, MD, discusses the challenges of mitigating antigen escape in mantle cell lymphoma.

Dr. Zalcberg on the Role of Ripretinib in Advanced GIST

November 10th 2020

John Zalcberg, PhD, OAM, discusses the role of Gastrointestinal Cancer in advanced gastrointestinal stromal tumor.

Dr. Cavnar on the Importance of Multidisciplinary Care in CRC

November 10th 2020

Michael J. Cavnar, MD, discusses the importance of multidisciplinary care in colorectal cancer.

Dr. Costello on Treatment Selection Considerations in Multiple Myeloma

November 10th 2020

Caitlin Costello, MD, discusses treatment selection considerations in multiple myeloma.

Dr. Ruan on the Incidence of MCL

November 10th 2020

Jia Ruan, MD, PhD, discusses the incidence of mantle cell lymphoma.

Dr. Danilov on the Role of Disease Biology in Up-front Treatment Selection in CLL

November 10th 2020

Alexey V. Danilov, MD, PhD, discusses the role of disease biology in up-front treatment selection in chronic lymphocytic leukemia.

Dr. Abdulkadir on the Challenges of Targeting MYC in Prostate Cancer

November 10th 2020

Sarki A. Abdulkadir, MD, PhD, discusses the challenges of targeting MYC in prostate cancer.